Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy

OncoImmunology

Volumn 3, Issue 5, 2014, Pages

  Grimaldi, Antonio M ^a   Simeone, Ester ^a   Giannarelli, Diana ^b   Muto, Paolo ^a   Falivene, Sara ^a   Borzillo, Valentina ^a   Giugliano, Francesca Maria ^a   Sandomenico, Fabio ^a   Petrillo, Antonella ^a   Curvietto, Marcello ^a   Esposito, Assunta ^a   Paone, Miriam ^a   Palla, Marco ^a   Palmieri, Giuseppe ^c   Caracò, Corrado ^a   Ciliberto, Gennaro ^a   Mozzillo, Nicola ^a   Ascierto, Paolo A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CNR   (Italy)

Author keywords

Abscopal; Combination; Expanded access; Ipilimumab; Melanoma; Radiotherapy

Indexed keywords

IPILIMUMAB;

ABSCOPAL EFFECT; ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; FEMALE; HUMAN; ITALY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY METASTASIS; OVERALL SURVIVAL; RADIATION RESPONSE; RETROSPECTIVE STUDY; SKIN METASTASIS; VERY ELDERLY;

EID: 84904061705     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28780     Document Type: Article

References (37)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
2. Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
3. Drake CG. Combination immunotherapy approaches. Ann Oncol 2012; 23(Suppl 8):viii41-6; PMID:22918927; http://dx.doi.org/10.1093/annonc/mds262
4. Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, Swetter SM, Knox SJ. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 2012; 5:404-7; PMID:23323154; http://dx.doi.org/10.1593/tlo.12280
5. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic antimelanoma immune response. Int J Radiat Oncol Biol Phys 2013; 85:293-5; PMID:22560555; http://dx.doi.org/10.1016/j.ijrobp.2012.03.017
6. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:925-31; PMID:22397654; http://dx.doi.org/10.1056/NEJMoa1112824
7. Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol 1953; 26:234-41; PMID:13042090; http://dx.doi.org/10.1259/0007-1285-26-305-234
8. Antoniades J, Brady LW, Lightfoot DA. Lymphangiographic demonstration of the abscopal effect in patients with malignant lymphomas. Int J Radiat Oncol Biol Phys 1977; 2:141-7; PMID:403163; http://dx.doi.org/10.1016/0360-3016(77)90020-7
9. Robin HI, AuBuchon J, Varanasi VR, Weinstein AB. The abscopal effect: demonstration in lymphomatous involvement of kidneys. Med Pediatr Oncol 1981; 9:473-6; PMID:7029238; http://dx.doi.org/10.1002/mpo.2950090510
10. Kingsley DP. An interesting case of possible abscopal effect in malignant melanoma. Br J Radiol 1975; 48:863-6; PMID:811297; http://dx.doi.org/10.1259/0007-1285-48-574-863
11. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58:862-70; PMID:14967443; http://dx.doi.org/10.1016/j.ijrobp.2003.09.012
12. Hodge JW, Sharp HJ, Gameiro SR. Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother Radiopharm 2012; 27:12-22; PMID:22283603; http://dx.doi.org/10.1089/cbr.2012.1202
13. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11:728-34; PMID:15701862
14. Knisely JPS, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 2012; 117:227-33; PMID:22702482; http://dx.doi.org/10.3171/2012.5.JNS111929
15. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013; 24:1813-21; PMID:23535954; http://dx.doi.org/10.1093/annonc/mdt107
16. Assi H, Wilson KS. Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases. Curr Oncol 2013; 20:e165-9; PMID:23559884; http://dx.doi.org/10.3747/co.20.1265
17. Balakan O, Süner A, Yiǧiter R, Balakan T, Sirikçi A, Sevinç A. Long-term survival in metastatic malignant melanoma: ipilimumab followed by vemurafenib in a patient with brain metastasis. Intern Med 2012; 51:2819-23; PMID:23037483
18. Bot I, Blank CU, Brandsma D. Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol 2012; 259:1976-8; PMID:22527228; http://dx.doi.org/10.1007/s00415-012-6488-4
19. Du Four S, Wilgenhof S, Duerinck J, Michotte A, Van Binst A, De Ridder M, Neyns B. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur J Cancer 2012; 48:3045-51; PMID:22727601; http://dx.doi.org/10.1016/j.ejca.2012.05.016
20. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyteassociated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008; 105:3005-10; PMID:18287062; http://dx.doi.org/10.1073/pnas.0712237105
21. Golden EB, Demaria S, SchiffPB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013; 1:365-72; PMID:24563870; http://dx.doi.org/10.1158/2326-6066.CIR-13-0115
22. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.1038/nm1622
23. Hagemann T, Balkwill F, Lawrence T. Inflammation and cancer: a double-edged sword. Cancer Cell 2007; 12:300-1; PMID:17936555; http://dx.doi.org/10.1016/j.ccr.2007.10.005
24. Higgins JP, Bernstein MB, Hodge JW. Enhancing immune responses to tumor-associated antigens. Cancer Biol Ther 2009; 8:1440-9; PMID:19556848; http://dx.doi.org/10.4161/cbt.8.15.9133
25. den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE. The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment. J Immunol 2004; 172:6074-9; PMID:15128791; http://dx.doi.org/10.4049/jimmunol.172.10.6074
26. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003; 170:6338-47; PMID:12794167; http://dx.doi.org/10.4049/jimmunol.170.12.6338
27. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203:1259-71; PMID:16636135; http://dx.doi.org/10.1084/jem.20052494
28. Demaria S, Pilones KA, Formenti SC, Dustin ML. Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology 2013; 2:e23127; PMID:23802063; http://dx.doi.org/10.4161/onci.23127
29. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15:5379-88; PMID:19706802; http://dx.doi.org/10.1158/1078-0432.CCR-09-0265
30. Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, Lee NY, Wolchok JD. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 2013; 1:92-8; PMID:24777500; http://dx.doi.org/10.1158/2326-6066.CIR-13-0082
31. Sullivan RJ, Lawrence DP, Wargo JA, Oh KS, Gonzalez RG, Piris A. Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. N Engl J Med 2013; 369:173-83; PMID:23841733; http://dx.doi.org/10.1056/NEJMcpc1302332
32. Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A, et al. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 2014; 50:121-7; PMID:24100024; http://dx.doi.org/10.1016/j.ejca.2013.09.007
33. Di Giacomo AM, Danielli R, Calabrò L, Bertocci E, Nannicini C, Giannarelli D, Balestrazzi A, Vigni F, Riversi V, Miracco C, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2011; 60:467-77; PMID:21170646; http://dx.doi.org/10.1007/s00262-010-0958-2
34. Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 2013; 62:1021-8; PMID:23591982; http://dx.doi.org/10.1007/s00262-013-1418-6
35. Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, RidolfiR, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, et al. Efficacy and safety of ipilimumab 3mg/kg in patients with pre-treated, metastatic, mucosal melanoma. Eur J Cancer 2013; 50:121-7; PMID:24100024
36. Queirolo P, Simeone E, De Galitiis F, Di Guardo L, Di Giacomo AM, Marconcini R, Ferraresi V, de Rosa F, Guida M, Stragliotto S. Efficacy and Safety Data from Patients with Advanced Melanoma and Brain Metastases Participating in the European Ipilimumab Expanded Access Programme (Eap) In Italy. Ann Oncol 2012; 23(Suppl. 9):ix369
37. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624